newsfilter
← Latest News
PR Newswire·

Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates

Pegzilarginase BLA submitted to the FDA; if approved, pegzilarginase would be the first FDA-approved treatment for Arginase 1 Deficiency Additional PEACE data supporting potential efficacy of pegzilarginase presented at SIMD Enrollment continues in